<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Matrix metalloproteinase-9 (MMP-9) is an important member of the matrix metalloproteinase family and is considered to be involved in the invasion and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Many studies were published to assess the prognostic role of MMP-9 overexpression in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but the findings from those studies were inconsistent </plain></SENT>
<SENT sid="2" pm="."><plain>We searched eligible studies in Pubmed, Embase, and Web of Science databases </plain></SENT>
<SENT sid="3" pm="."><plain>Thirteen studies with a total of 2, 390 CRC patients were finally included into the meta-analysis </plain></SENT>
<SENT sid="4" pm="."><plain>The pooled hazard ratios (HRs) with the corresponding 95 % confidence interval (95 % CIs) for overall and progression-free survival were calculated by using meta-analysis </plain></SENT>
<SENT sid="5" pm="."><plain>There were nine studies with a total of 1,674 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients relating the progression-free survival, and eight studies with a total of 1,379 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients relating the overall survival </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, MMP-9 overexpression was associated with poorer progression-free survival in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (fixed-effects HR 1.81, 95 % CI 1.48-2.20, P &lt; 0.001; random-effects HR 1.92, 95 % CI 1.46-2.53, P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, MMP-9 overexpression was also associated with poorer overall survival in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (fixed-effects HR 1.74, 95 % CI 1.39-2.19, P &lt; 0.001; random-effects HR 1.78, 95 % CI 1.31-2.41, P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>MMP-9 expression is associated with the prognosis of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and patients with higher MMP-9 expression have poorer survival </plain></SENT>
</text></document>